Antipyretics

Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market

Retrieved on: 
Tuesday, August 3, 2021

The re-launch of Dr. Reddys Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products, says Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories.

Key Points: 
  • The re-launch of Dr. Reddys Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products, says Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories.
  • Dr. Reddys OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer.
  • Dr. Reddys Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

Retrieved on: 
Wednesday, July 28, 2021

"The findings from this study demonstrate the ability of ZYNRELEF to serve as the foundation of non-opioid multimodal analgesia.

Key Points: 
  • "The findings from this study demonstrate the ability of ZYNRELEF to serve as the foundation of non-opioid multimodal analgesia.
  • ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which:
    can increase the risk of a heart attack or stroke that can lead to death.
  • Of the 98% of patients who completed the TSQM-9, most patients were "very" or "extremely" satisfied with their MMA regimen.
  • ZYNRELEF plus acetaminophen and ibuprofen was well tolerated; safety results were similar between concurrent and alternating MMA cohorts.

Sales of OTC Remedies for Colds & Coughs Climb as Face Mask Sales Decline

Retrieved on: 
Monday, June 21, 2021

"With face masks coming off, sales of OTC remedies for coughs, colds and allergies on the rise."

Key Points: 
  • "With face masks coming off, sales of OTC remedies for coughs, colds and allergies on the rise."
  • This behavior has also been credited for cutting down on the number of people suffering from more commonly transmitted colds and coughs over the past year.
  • Meanwhile, sales of children's analgesics climbed 78 percent during that same timeframe, with Motrin up 96% and Tylenol up 76%.
  • Meanwhile, allergy sufferers who are back to spending more time outdoors have been buying more OTC remedies this year than they did last.

Global Paracetamol (CAS 103-90-2) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021

The "Paracetamol (CAS 103-90-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Paracetamol (CAS 103-90-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Paracetamol market trends and forecast, distinguish Paracetamol manufacturers and suppliers.
  • The Paracetamol global market report key points:

BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available

Retrieved on: 
Wednesday, December 16, 2020

Combogesic is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults.

Key Points: 
  • Combogesic is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults.
  • Combining two trusted, familiar, and effective active ingredients, acetaminophen and ibuprofen, in a new patented formulation, Combogesic brings together two different modes of action into one effective pain reliever.
  • Though the two active ingredients have been available in Canada for decades, Combogesic represents the first Health Canada approved combination of these proven pain relievers in a single tablet.
  • The efficacy of Combogesic is based on its clinically proven unique ratio one tablet contains 325 mg of acetaminophen and 97.5 mg of ibuprofen, a 3.3:1 ratio.

Chronic Pain Treatment Markets, 2030 - Epidemiological Analysis, Pricing and Reimbursement, Research Funding and Government Initiatives, Pipeline, Product Launches, Treatment

Retrieved on: 
Monday, December 7, 2020

DUBLIN, Dec. 7, 2020 /PRNewswire/ -- The "Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 7, 2020 /PRNewswire/ -- The "Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate a revenue of $151.7 billion in 2030.
  • The players operating in the chronic pain treatment market are increasingly focusing on product launches for gaining foothold in the market.
  • The FDA approval made this product the first prescription-strength NSAID topical gel for arthritis pain available OTC in the U.S.

NextGen Healthcare Named Only Ambulatory-Specific EMR Vendor to Provide Strong Usability Experience in Latest KLAS Interoperability Report

Retrieved on: 
Thursday, November 12, 2020

NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced it is the only ambulatory-specific vendor recognized for providing a strong usability experience for all interoperability workflows measured in the latest KLAS Research Interoperability 2020 Acute/Ambulatory Report .

Key Points: 
  • NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced it is the only ambulatory-specific vendor recognized for providing a strong usability experience for all interoperability workflows measured in the latest KLAS Research Interoperability 2020 Acute/Ambulatory Report .
  • The KLAS report states, Over the last 18 months, NextGen Healthcare has made significant progress in enabling data reconciliation and the ingestion of progress notes and lab data.
  • This recognition from KLAS is the culmination of over a decade of interoperability and usability development, said Rusty Frantz, chief executive officer for NextGen Healthcare.
  • In the report, KLAS found that NextGen Healthcare offers the best experience for automatic reconciliation of duplicate medications, even for inexact matches (e.g., Tylenol vs. acetaminophen).

DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment

Retrieved on: 
Tuesday, November 10, 2020

Californias OEHHA is assessing whether or not the common analgesic acetaminophen (a.k.a., APAP or paracetamol) should be labeled as carcinogenic to humans.

Key Points: 
  • Californias OEHHA is assessing whether or not the common analgesic acetaminophen (a.k.a., APAP or paracetamol) should be labeled as carcinogenic to humans.
  • DILIsym modeling supports key drug development decisions by predicting potential drug-induced liver injury (DILI) risk of new drug candidates.
  • DILIsym is the product of an ongoing public-private partnership (the DILI-sim Initiative ), involving scientists from the pharmaceutical industry and academia.
  • The OEHHA review of this affordable over-the-counter drug for the possible threat of carcinogenicity is an important effort for DILIsym to play a role in through the CHPA submission.

Advil Taps Leading Lady and Super Mom Angela Kinsey for the Launch of Major Pain Innovation, Advil Dual Action

Retrieved on: 
Wednesday, September 9, 2020

I know I can rely on Advil Dual Action to alleviate my pain."

Key Points: 
  • I know I can rely on Advil Dual Action to alleviate my pain."
  • While Kinsey has found relief in new Advil Dual Action since she began using it this summer, other pain sufferers have not.
  • "We are excited to bring that to market in our newest innovation, Advil Dual Action, so people everywhere can find relief.
  • Advil Dual Action is an exclusive pain-fighting formula, combining ibuprofen and acetaminophen to fight pain in two ways.

Nuvo Pharmaceuticals® Announces The Canadian Commercial Launch of Suvexx™ - For The Acute Treatment of Migraine

Retrieved on: 
Wednesday, September 9, 2020

Suvexx (sumatriptan succinate and naproxen sodium tablets) is a fixed-dose combination prescription medication, indicated for the acute treatment of migraine attacks with or without aura in adults.

Key Points: 
  • Suvexx (sumatriptan succinate and naproxen sodium tablets) is a fixed-dose combination prescription medication, indicated for the acute treatment of migraine attacks with or without aura in adults.
  • Suvexx helps patients manage acute migraine attacks using a combination of sumatriptan succinate and naproxen sodium in a single tablet.
  • "The entry of Suvexx into the Canadian market provides migraine sufferers with an innovative treatment for acute migraine supported by strong clinical data.
  • Suvexx, a combination of sumatriptan succinate and naproxen sodium in a single tablet, provides a novel approach for treating acute migraine.